Physician profile
Jack Englert
NPI 1558324186
$36,584.97
in general payments reported to CMS, 2019-2025
56 companies · $3,768 in 2025
The $3,768 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,930 · 2020: $7,194 · 2021: $9,205 · 2022: $6,630 · 2023: $3,454 · 2024: $3,403 · 2025: $3,768.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,604.77 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $12,763.84 | 2019-2022 | |
| Novo Nordisk INC | $4,191.08 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $3,572.49 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $1,752.33 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $1,107.87 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Amgen INC. | $932.47 | 2019-2025 | Repatha, Otezla, Otezla |
| Kowa Pharmaceuticals America, INC. | $810.29 | 2019-2025 | Zoryve, Livalo, Seglentis |
| Lilly USA, LLC | $795.30 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $760.04 | 2019-2025 | |
| Axsome Therapeutics, INC. | $754.52 | 2023-2025 | Auvelity, Sunosi |
| Astellas Pharma US INC | $746.41 | 2019-2025 | Veozah, Myrbetriq |
| Allergan, INC. | $711.25 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $647.09 | 2021-2025 | Rexulti, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $597.72 | 2022-2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $550.39 | 2019-2025 | Xifaxan |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $517.41 | 2021-2025 | |
| Amarin Pharma, INC. | $489.11 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $450.66 | 2019-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $410.18 | 2019-2025 | Spravato |
| Vanda Pharmaceuticals INC. | $343.43 | 2024-2025 | Fanapt |
| Antares Pharma, INC. | $296.92 | 2019-2023 | Xyosted, Tlando, Nocdurna |
| Phathom Pharmaceuticals, INC. | $250.15 | 2024-2025 | Voquezna |
| Corcept Therapeutics | $236.15 | 2023-2025 | Korlym |
| Abbott Laboratories | $235.95 | 2021-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $233.61 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $200.38 | 2022 | |
| Merck Sharp & Dohme LLC | $195.07 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $184.80 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $174.14 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $157.42 | 2022-2024 | Quviviq |
| Tolmar, INC. | $151.30 | 2023-2025 | Jatenzo |
| Lundbeck LLC | $148.88 | 2023-2025 | Rexulti |
| Currax Pharmaceuticals LLC | $147.54 | 2019-2024 | Contrave, Nexlizet, Nexletol |
| Novartis Pharmaceuticals Corporation | $112.20 | 2019-2022 | |
| Vivus LLC | $90.40 | 2019-2020 | |
| Almatica Pharma LLC | $72.31 | 2024-2025 | Loreev Xr |
| Biohaven Pharmaceuticals, INC. | $67.72 | 2021 | |
| Aytu Biopharma, INC. | $66.12 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $66.09 | 2021-2022 | |
| Intra-Sana Laboratories | $64.18 | 2022-2023 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Adlon Therapeutics L.P. | $58.41 | 2020-2021 | |
| Dexcom, INC. | $56.75 | 2022 | |
| Exact Sciences Corporation | $55.37 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sumitomo Pharma America, INC. | $44.11 | 2024-2025 | Gemtesa |
| Teva Pharmaceuticals USA, INC. | $43.00 | 2019-2020 | |
| Alk-Abello, INC | $41.90 | 2024 | Odactra, Ragwitek, Grastek |
| Biogen, INC. | $34.15 | 2021-2022 | |
| Esperion Therapeutics, INC. | $29.29 | 2025 | Nexletol |
| Alkermes, INC. | $27.65 | 2025 | Aristada, Lybalvi |
| E.R. Squibb & Sons, L.L.C. | $26.56 | 2019-2021 | |
| Insulet Corporation | $25.52 | 2021 | |
| Medicure Pharma INC. | $22.59 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $20.88 | 2025 | Rexulti |
| Horizon Therapeutics Plc | $15.81 | 2021 | |
| Neos Therapeutics, Lp | $15.79 | 2022 | |
| Redhill Biopharma INC. | $11.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Englert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.